Malaria: Confronting Challenges From Drug Discovery to Treatment
Scientific Organizers: David A. Fidock, Kelly Chibale and Elizabeth A. Ashley
Date: April 10 - 13, 2022
Location: Beaver Run Resort, Breckenridge, CO, USA
For important information on the coronavirus, please click here
This proposed symposium addresses the pressing need to accelerate the development of new antimalarials that can treat Plasmodium falciparum parasites that have acquired resistance to existing first-line drugs. Specific aims are to: • Review recent innovations in antimalarial drug discovery. • Examine preclinical and clinical models to test compounds in development. • Review the efficacy of ACTs across different endemic settings and discuss current approaches to reducing the disease burden. • Review the current status of antimalarial resistance, including mechanistic studies and how they inform our understanding of drug modes of action. • Discuss new medicines, and prophylaxis, treatment and transmission-blocking strategies. Bringing together experts in drug discovery and development, mechanistic studies into drug modes of action and mechanisms of resistance, and field-based clinician-investigators and modelers will inform attendees on the multiple aspects required to proceed from drug discovery through to development and learn about the current status of ACT efficacy in the field and how to respond to challenges posed by the emergence of antimalarial resistance. This forum will allow scientists in basic or applied research to exchange knowledge and ideas with field-based researchers and clinicians. No other forum addresses this niche in a concentrated forum. The goal is to identify new areas of collaboration and new approaches to overcome resistance. Some researchers also attend the ~4,000 strong ASTMH annual meeting, although it is not structured to enable close networking and data sharing that a Keystone Symposium provides.
Scholarship Deadline: December 20 2021 details
Keystone Symposia is committed to maintaining a positive and respectful environment at its meetings. To this end, please review and comply with our policies